Retinal biomarkers for neurodegenerative disease

Retinal biomarkers for neurodegenerative disease use eye-scan technologies to detect signals of Alzheimer’s and related conditions directly in retinal tissue, exploiting the retina’s direct neural and vascular connection to the brain as a non-invasive, accessible proxy for pathology that would otherwise require PET imaging or cerebrospinal-fluid sampling. RetiSpec’s AI-driven hyperspectral eye test analyzes subtle spectral signatures in retinal tissue associated with Alzheimer’s disease, with the company recently closing a $10 million USD round to advance commercialization and its underlying hyperspectral-imaging technology documented in a dedicated patent filing. Optina Diagnostics develops a related hyperspectral retinal-imaging approach for Alzheimer’s biomarker detection, co-published in the same multi-site Alzheimer’s Research & Therapy study and running an active registered clinical trial. Heidelberg Engineering’s Spectralis OCT platform, an established retinal-imaging system originally built for ophthalmology, is now widely used as a research and clinical tool for OCT-based structural and vascular biomarkers linked to neurodegenerative disease, documented across multiple 2026 publications including JAMA Ophthalmology. NeuroVision Imaging’s retinal amyloid-imaging technology targets amyloid-beta deposits detectable in the retina, part of the same expanding multi-site research literature validating retinal biomarkers against established Alzheimer’s diagnostic measures.

The key directions of retinal biomarkers for neurodegenerative disease are:

1. Hyperspectral retinal imaging (Hyperspectral Retinal Imaging): capturing a full spectral signature (not just a color image) of retinal tissue to detect subtle Alzheimer’s-associated changes invisible to conventional imaging — RetiSpec, Optina Diagnostics.
2. OCT-based neurodegenerative biomarkers (OCT Neurodegenerative Biomarkers): optical coherence tomography measuring retinal nerve fiber layer thickness and vascular density as structural proxies for neurodegeneration — Heidelberg Engineering’s Spectralis platform.
3. Retinal amyloid imaging (Retinal Amyloid Imaging): detecting amyloid-beta deposits directly in retinal tissue, mirroring the amyloid pathology central to Alzheimer’s diagnosis — NeuroVision Imaging.
4. AI-driven multi-site biomarker validation (AI Retinal Biomarker Validation): machine-learning classifiers trained and validated across multi-site clinical studies to establish retinal-biomarker correlation with confirmed neurodegenerative-disease status.

Sectoral value chain#

[retinal imaging technology development] ──> [multi-site clinical validation studies] ──> [regulatory clearance]
                                                    │
                                       (clinical/screening deployment)
                                                    │
                                                    ▼
[integration into neurodegenerative diagnostic pathway] <─── [AI biomarker classification & report] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Hyperspectral imaging (Hyperspectral Retinal Imaging): capturing dozens to hundreds of spectral bands across the retina reveals tissue-composition changes invisible to standard RGB fundus photography, the core RetiSpec/Optina Diagnostics approach.
• Optical coherence tomography (OCT Neurodegenerative Biomarkers): high-resolution cross-sectional retinal imaging measures nerve fiber layer thinning and microvascular changes correlated with neurodegenerative disease progression.
• Retinal amyloid detection (Retinal Amyloid Imaging): imaging techniques targeting amyloid-beta deposits in retinal tissue provide a proxy for the amyloid plaque burden central to Alzheimer’s pathology.

The stack applies three distinct optical principles to the same underlying goal — reading neurodegenerative-disease pathology out of retinal tissue non-invasively — hyperspectral signature analysis, structural/vascular OCT imaging, and amyloid-specific detection.

1. AI-driven hyperspectral analysis (Hyperspectral Retinal Imaging):
   • RetiSpec and Optina Diagnostics both capture full spectral signatures across the retina and apply machine-learning classifiers to detect subtle tissue-composition changes associated with Alzheimer’s disease, validated in shared multi-site clinical research.
2. OCT structural and vascular biomarkers (OCT Neurodegenerative Biomarkers):
   • Heidelberg Engineering’s Spectralis platform measures retinal nerve fiber layer thickness and microvascular density, structural proxies increasingly correlated with neurodegenerative disease progression in published clinical research.
3. Retinal amyloid detection (Retinal Amyloid Imaging):
   • NeuroVision Imaging’s technology targets amyloid-beta deposits in retinal tissue, mirroring the amyloid-plaque pathology central to Alzheimer’s diagnosis without requiring brain PET imaging.
4. Multi-site clinical validation (AI Retinal Biomarker Validation):
   • RetiSpec and Optina Diagnostics’ co-published, multi-site Alzheimer’s Research & Therapy study illustrates the category’s shared push toward large validated cohorts as the evidence bar for eventual regulatory clearance.